Coherus BioSciences, Inc. (CHRS)
After hours:
| Previous Close | 2.1800 |
| Open | 2.1000 |
| Bid | 2.1800 x 200 |
| Ask | 2.2000 x 500 |
| Day's Range | 2.1000 - 2.2450 |
| 52 Week Range | 1.4300 - 8.2200 |
| Volume | |
| Avg. Volume | 2,751,958 |
| Market Cap | 247.426M |
| Beta (5Y Monthly) | 0.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5300 |
| Earnings Date | May 06, 2024 - May 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.43 |
Simply Wall St.Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 83% over the last five years
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
GlobeNewswireCoherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion –– Mechanism may enhance antitumor responses with immunotherapy –– First novel immuno-oncology product candidate discovered and developed by Coherus –– The CHS-1000 IND submission is planned for Q2 2024 – REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq
Insider MonkeyCoherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript March 13, 2024 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is $-0.62 EPS, expectations were $-0.21. CHRS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank […]
